We are a spin-off of the École normale supérieure - PSL, focused on in silico drug discovery. We combine AI and disruptive structure-based affinity algorithms, which are both accurate and 10,000x faster than competition, to generate lead-like molecules for a given target.
We collaborate with innovative R&D pharmaceutical companies, biotechs & CROs and seek to build our own portfolio with dozens of internal projects. We focus on identifying or generating molecules of interest for a given project and do not sell our technology as software.
We are seeking highly skilled, motivated and curious individuals to develop our unique science to discover new therapeutic molecules!